Close
FINDING CURES TOGETHER<sup>SM</sup>

Intestinal Stem Cells and Colon Cancer: Biology to Therapy

​Program 

Thursday, Sept. 27

Friday, Sept. 28

Saturday, Sept. 29

Sunday, Sept. 30


Thursday, Sept. 27

Opening Keynote Session
Welcome Remarks and Session Chair: Anil Rustgi, University of Pennsylvania, Philadelphia, Pennsylvania
6-7 p.m.

Lgr5 stem cell-based organoids in cancer research
Hans Clevers, Hubrecht Institute, Utrecht, The Netherlands


Welcome Reception
7-9 p.m.


Friday, Sept. 28

Continental Breakfast with Mentoring Roundtables
7-8 a.m.


Plenary Session 1: Intestinal Stem Cells – Biology to Model Systems to Opportunities for Therapeutics I
Session Chair: Owen Sansom, Beatson Institute for Cancer Research, Glasgow, United Kingdom
8-10 a.m.

Targeting transformed intestinal stem cells in vivo
Owen Sansom

Intestinal lineage tracing from mouse stem cells to human mutation burden
Douglas Winton, Cancer Research UK Cambridge Institute, Cambridge, United Kingdom

Msi proteins and the stem cell origins of colon cancer
Christopher Lengner, University of Pennsylvania School of Veterinary Medicine, Philadelphia, Pennsylvania

Real-time in vivo imaging of the intestinal epithelium reveals that stem cell and crypt dynamics affect mutation accumulation*
Lotte Bruens, Netherlands Cancer Institute, Amsterdam, The Netherlands

LGR4 is mechanistically different from LGR5 in potentiating Wnt/β-catenin signaling*
Soohyun Park, University of Texas Health Science Center at Houston, Houston, Texas


Break
10-10:30 a.m.


Plenary Session 2: Intestinal Stem Cells – Biology to Model Systems to Opportunities for Therapeutics II
Session Chair: Anil Rustgi, University of Pennsylvania, Philadelphia, Pennsylvania
10:30 a.m.-12:30 p.m.

Epigenetic control of intestinal stem and progenitor cell states
Ramesh A. Shivdasani, Dana-Farber Cancer Institute, Boston, Massachusetts

Targeting macrophages facilitates reduction of cancer stem cells and tumor regrowth
Linheng Li, Stowers Institute for Medical Research, Kansas City, Missouri

Dynamic regulation of cellular identity in normal and cancerous tissues
Kim B. Jensen, University of Copenhagen, Copenhagen, Denmark

HMGA1 is upregulated by procarcinogenic bacteria within the microbiome to expand the colon stem cell pool and drive tumorigenesis*
Linda Resar, The Johns Hopkins University School of Medicine, Baltimore, Maryland

Injury-induced Paneth cell plasticity*
Nan Gao, Rutgers University, Newark, New Jersey


Poster Session A / Lunch
12:30-3 p.m.


Plenary Session 3: Signaling Pathways and the Stem Cell Niche
Session Chair: Christina Curtis, Stanford University, Stanford, California
3-5 p.m.

A novel, non-germline role for the PIWI component, Aubergine, in intestinal stem cell proliferation during tissue regeneration
Julia Cordero, University of Glasgow, Glasgow, United Kingdom

Gremlins in the crypt: BMP signaling in colorectal tumorigenesis
Simon Leedham, University of Oxford, Oxford, United Kingdom

Immune evasion and metastasis in colorectal cancer
Eduard Batlle, Institute for Research in Biomedicine, Barcelona, Spain

Cancer cell plasticity drives metastasis in colorectal cancer*
Arianna Fumagalli, NKI-AvL, Oncode Institute, Amsterdam, The Netherlands

Epithelial Notch1 drives metastasis by controlling neutrophil chemotaxis in novel late stage colorectal cancer genetically engineered mouse models*
Rene Jackstadt, Cancer Research UK Beatson Institute, Glasgow, United Kingdom


Top of page


Saturday, Sept. 29

Continental Breakfast with Mentoring Roundtables
7-8 a.m.


Keynote Lecture
Session Chair: Hans Clevers, Hubrecht Institute, Utrecht, The Netherlands
8-9 a.m.

The mutational landscape of normal colorectal epithelium
Michael Stratton, Wellcome Trust Sanger Institute, Cambridge, United Kingdom


Plenary Session 4: Genetic and Genomic Alterations in Colon Cancer I
Session Chair: Christina Curtis, Stanford University, Stanford, California
9-10:30 a.m.

Quantifying the evolutionary dynamics of colorectal cancer progression
Christina Curtis

RNA-binding proteins and colon cancer pathogenesis
Anil Rustgi, University of Pennsylvania, Philadelphia, Pennsylvania

Defining sensitivity and resistance to WNT inhibitors using CRISPR editing in intestinal organoids and in vivo models*
Lukas Dow, Weill Cornell Medicine, New York, New York

Trajectory space analysis: Leveraging computational models and single-cell RNAseq to understand genetic programs defining intestinal lineages and infer colon stem cells in mouse*
Denis Dermadi Bebek, Stanford University, Palo Alto, California


Break
10:30-11 a.m.


Plenary Session 5: Genetic and Genomic Alterations in Colon Cancer II
Session Chair: Anil Rustgi, University of Pennsylvania, Philadelphia, Pennsylvania
11 a.m.-1 p.m.

Microbiome in PTEN hamartoma tumor syndrome
Charis Eng, The Cleveland Clinic, Cleveland, Ohio

Organoid modeling of tumor cells and their microenvironment
Calvin J. Kuo, Stanford University, Stanford, California

Clonal competition and collaboration in colorectal cancer
Eric R. Fearon, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan

Intestinal cancer initiation using ENU mutagenesis*
Filipe Lourenco, CRUK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom

PLAGL2 is a let-7 target that drives intestinal stem cell fate and transformation*
Blair Madison, Washington University in St. Louis, St. Louis, Missouri


Poster Session B / Lunch
1-3:30 p.m.


Plenary Session 6: Risk Stratification as a Basis for Targeted Therapy in Colon Cancer
Session Chair: Owen Sansom, Beatson Institute for Cancer Research, Glasgow, United Kingdom
3:30-5:30 p.m.

New predictive biomarkers for colorectal cancer
Timothy Maughan, CRUK/MRC Oxford Institute for Radiation Oncology, Oxford, England

Risk stratification as a basis for targeted therapy in colon cancer
Rodrigo Dienstmann, Vall d'Hebron University Hospital, Barcelona, Spain

The molecular underpinnings of sidedness in determining cancer therapy: What is “right”?
Nilofer S. Azad, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland

KRAS-IRF2 axis drives immune suppression and immune therapy resistance in colorectal cancer*
Y. Alan Wang, The University of Texas MD Anderson Cancer Center, Houston, Texas

Ex vivo pharmacogenomic heterogeneity of colorectal liver metastases*
Kushtrim Kryeziu, Institute for Cancer Research and K.G. Jebsen Colorectal Cancer Research Centre, Oslo University Hospital, Oslo, Norway


Sunday, Sept. 30

Continental Breakfast with Mentoring Roundtables
7-8 a.m.


Plenary Session 7: Targeted and Combination Therapies
Session Chair: Johanna C. Bendell, Sarah Cannon Research Institute, Nashville, Tennessee
8-10 a.m.

The who, what, when, and why of adjuvant therapy for colon cancer
Johanna C. Bendell

Therapeutic resistance and tumor heterogeneity in colorectal cancer
Ryan Corcoran, Massachusetts General Hospital Cancer Center, Boston, Massachusetts

Targeting intestinal stem cells in cancer
Frederic J. de Sauvage, Genentech, South San Francisco, California

New therapeutic strategies to target colon cancer stem cells
Heinz-Josef Lenz, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California


Break
10-10:15 a.m.


Plenary Session 8: Technology, Therapy, and Trials
Session Chair: Hans Clevers, Hubrecht Institute, Utrecht, The Netherlands
10:15 a.m.-12:15 p.m.

Patient-derived organoids en route to the clinic
Nicola Valeri, Royal Marsden Hospital Institute of Cancer Research, Sutton, United Kingdom

Inactivation of DNA repair triggers immune surveillance in colorectal cancers
Alberto Bardelli, University of Torino, Torino, Italy

The colorectal cancer microbiome
Matthew Meyerson, Dana-Farber Cancer Institute, Boston, Massachusetts

Circulating tumor DNA in colorectal cancer management: Assessing minimal residual disease and treatment response
Scott Kopetz, The University of Texas MD Anderson Cancer Center, Houston, Texas


Closing Remarks
12:15 p.m.


*Short talk from proffered abstract


Top of page